Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9999183 | 0.81 | PTGES (0.34) | KMT2A | |
| SCHEMBL115839 | 0.80 | SMN1; SMN2 (0.35) | LMNAHPGDSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29936639 | 0.80 | SMN1; SMN2 (0.35) | LMNAHPGDSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL25871834 | 0.80 | SMN1; SMN2 (0.35) | LMNAHPGDSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL24809655 | 0.77 | TSHR (0.32) | MAPTKMT2A | |
| SCHEMBL29813282 | 0.77 | MEN1 (0.31) | MAPTKMT2A | |
| SCHEMBL23486175 | 0.76 | GABRA1 (0.37) | LMNAHPGDALDH1A1HTTCYP1A2 | |
| SCHEMBL23182669 | 0.76 | TSHR (0.31) | MAPTKMT2A | |
| SCHEMBL11023399 | 0.65 | PDE3B (0.43) | LMNAHPGDSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL12763937 | 0.65 | PGK1 (0.44) | LMNAMAPTALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314249-B2 | Process for the preparation of [4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-thiazolo-2-yl]-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20120083608-A1 | PROCESS FOR THE PREPARATION OF [4-(2-CHLORO-4- METHOXY-5-METHYLPHENYL)-5-METHYL-THIAZOLO-2-YL]-[2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)-ETHYL]-AMINE | SANOFI (FR) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083608-A1 | PROCESS FOR THE PREPARATION OF [4-(2-CHLORO-4- METHOXY-5-METHYLPHENYL)-5-METHYL-THIAZOLO-2-YL]-[2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)-ETHYL]-AMINE | CYP4B1, CYP3A4, CYP4F2 | LMNA 3275/4885HPGD 3160/4885SMN1; SMN2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.